Characterization of Hemolysin of *Moraxella bovis* Using a Hemolysis-Neutralizing Monoclonal Antibody

F. MARK BILLSON,† COLIN HARBOUR, WOJTEK P. MICHALSKI, JAN M. TENNENT, JOHN R. EGERTON, AND JENNIFER L. HODGSON

Department of Veterinary Clinical Sciences, University of Sydney, Camden, New South Wales 2570; Department of Infectious Diseases, University of Sydney, Sydney 2000; and CSIRO, Division of Animal Health, Australian Animal Health Laboratory, Geelong, Victoria 3220, Australia

Received 23 November 1999/Returned for modification 17 January 2000/Accepted 20 March 2000

A concentrated bacterial culture supernatant from the hemolytic *Moraxella bovis* strain UQV 148NF was used to immunize mice and generate monoclonal antibodies (MAbs). One, MAb G3/D7, neutralized the hemolytic activity of *M. bovis* and recognized a 94-kDa protein by Western blot analysis in hemolytic *M. bovis* strains representing each of the different fimbrial serogroups. Exposure of corneal epithelial cells to *M. bovis* concentrated culture supernatants demonstrated a role for an exotoxin in the pathogenesis of infectious bovine keratoconjunctivitis, while neutralization of hemolytic and cytotoxic activities by MAb G3/D7 implies that these activities are related or have common epitopes. The action of *M. bovis* hemolysin was further characterized in sheep erythrocyte preparations with a binding step and Ca\(^{2+}\) required for lysis to proceed, similar to the RTX family of bacterial exotoxins. Neutralization of lytic activity in vitro is evidence for the presence of *M. bovis* antigens, which may be capable of protecting cattle from the development of infectious bovine keratoconjunctivitis.

*Moraxella bovis* is a gram-negative bacterium implicated in the pathogenesis of infectious bovine keratoconjunctivitis (IBK), a disease causing significant economic losses in cattle industries worldwide (10, 35, 37). Strains of *M. bovis* must be fimbriated and hemolytic in cell culture to cause clinical disease, suggesting that these characteristics are important virulence traits. Fimbriae mediate attachment to corneal epithelium (28), while toxin production may cause corneal epithelial cell damage (16, 34).

The role of these virulence traits in disease implies the potential of these proteins as vaccine candidates. To date, most investigations have used fimbrial proteins in vaccine preparations, and both native and recombinant *M. bovis* fimbriae induce serogroup-specific protection (22, 23). However, there is increasing evidence that inclusion of fimbriae from all seven identified serogroups is necessary for protection, which may lead to antigenic competition (33). Therefore, the aim of this investigation was to characterize the hemolysin of *M. bovis* and assess its potential as an alternative vaccine candidate, as described for other bacterial hemolysins (30).

There has been limited characterization of the hemolysin of *M. bovis* with previous investigations associating hemolytic activity in cell-free preparations to fractions with molecular mass greater than 300 kDa (6). This has been attributed to its release in membrane-bound vesicles and association with cell-wall proteins and has foiled efforts to obtain purified toxin (3). However, several similarities have been observed between the activity of *M. bovis* hemolysin and the activity of recently documented family of pore-forming bacterial toxins, the RTX exotoxins (1, 4, 11, 15). These activities include pore formation in target-cell membranes and a role for Ca\(^{2+}\) in the lytic activity of *M. bovis* hemolysin (11). Members of the RTX toxin family include the secreted toxins of *Escherichia coli*, *Pasteurella hemolytica*, *Actinobacillus pleuroneumoniae*, and *Actinobacillus actinomycetemcomitans* (36, 39). Speculation that the hemolysin of *M. bovis* may be related to this toxin family has been supported by preliminary findings that a monoclonal antibody (MAb) recognizing *E. coli* hemolysin also recognizes a 100-kDa protein in hemolytic *M. bovis* cultures (16). However, the inclusion of the hemolysin of *M. bovis* in this toxin family has not been confirmed (21).

In addition to lytic action on erythrocytes, in vitro exposure of bovine corneal epithelial cells to culture supernatants of hemolytic *M. bovis* strains results in cell lysis (16, 19, 20). Although nonhemolytic *M. bovis* strains do not cause epithelial cell lysis, it is not known whether the loss of hemolytic phenotype alone is responsible for the observed loss of cytotoxicity. Consequently, a possible role for separate hemolytic and cytotoxic proteins in the pathogenesis of IBK has been debated (16, 19, 20).

Here, we report the generation of a MAb which neutralizes both the hemolytic and epithelial cytotoxic potential of *M. bovis* culture supernatants. This MAb was used to identify the putative hemolysin in cell-free extracts of hemolytic *M. bovis* strains by Western blot analysis and to investigate a role for Ca\(^{2+}\) in lytic activity of the hemolysin of *M. bovis* following exposure to erythrocytes.

### MATERIALS AND METHODS

**Bacterial strains and toxin preparation.** Seven field strains of hemolytic *M. bovis* representing the different fimbrial serogroups were used (serogroup A, strain 276; serogroup B, serogroup 3WO7; serogroup C, Dal2d; serogroup D, 593L; serogroup E, TAT 849; serogroup F, 218R; and serogroup G, Fleur 462 [27]). Two nonfimbriated *M. bovis* variants were also used, one hemolytic, UQV 148NF, and one nonhemolytic, Gordon 26L3 (3). To maximize hemolysin production, *M. bovis* cultures were grown in Mueller-Hinton broth (Oxoid, Basingstoke, Hertshire, United Kingdom) and were harvested in late log phase (6) with whole cells pelleted by centrifugation at 10,000 × *g* for 30 min at 4°C. Culture supernatants were volume concentrated by tangential ultrafiltration across a Minitan-S low-protein-binding cellulose membrane (Millipore, Sydney, Austra-
lia) with a 300-kDa cutoff as previously described (6), and the resulting concentrated culture supernatants (CCS) and filtrates (<300 kDa) were used in investigations. In some experiments, further concentration of CCS was achieved by subjecting samples to ultracentrifugation at 100,000 g for 6 h at 4°C. Following ultracentrifugation, the resulting pellet contained >90% of hemolytic activity and was used in investigations, while the supernatant was discarded.

**MAB production.** Three female BALB/c mice were immunized intraperitoneally on days 1, 28, and 42 with 9 μg of CCS from hemolytic *M. bovis* strain UQV 148NF and were incubated at 4°C overnight. Following blocking in 5% sodium caseinate in phosphate-buffered saline (PBS), hybridoma culture supernatants were added, and plates were incubated for 1 h at 37°C. Rabbit anti-murine immunoglobulin G (IgG)-alkaline phosphatase (Sigma Chemical Co., St. Louis, Mo.) was added, and plates were incubated for 1 h before the addition of substrate (p-nitrophenyl) phosphate disodium ([Sigma] dissolved in 1 M diethanolamine-HCl buffer [pH 9.8]) and measurement of absorbance at 405 nm. Plates were washed three times between each step by using PBS with 0.05% Tween 20. Controls included serum from CCS-immunized mice and culture supernatant from transfected X653 myeloma cell cultures.

**Determination of hemolytic activity.** The hemolytic activity of CCS was assessed by using a hemolytic assay as previously described (3). Briefly, twofold dilutions of CCS were made in 96-well microtiter plates, and an equal volume of a 1% solution of fresh, defibrinated sheep erythrocytes in PBS (sRBC) was added. Plates were incubated for 3 h at 37°C, and hemolysis was assessed visually. For detecting neutralization of hemolytic activity, CCS was incubated with hybridoma culture supernatant for 1 h at 37°C prior to the addition of sRBC as previously described (6). Controls included sera from nonimmunized mice, myeloma culture supernatant from cell line X653, and PBS.

The hemolytic activity of CCS over time was also investigated, and the role of Ca²⁺ was examined. CCS (1.2 μg) from hemolytic *M. bovis* strain UQV 148NF was incubated in the presence of PBS, EGTA (10 mM), or MAb G3/D7 for 1 h at 37°C prior to centrifugation at 12,000 g for 5 min and addition to sRBC. Incubation was continued for a further 1 h at 37°C with aliquots collected at 0, 5, 10, 20, 25, and 60 min and subjected to centrifugation at 12,000 × g for 5 min. The extent of sRBC lysis was determined by hemoglobin release into supernatants, with absorbance measured at 545 nm. sRBC-membrane pellets were collected after centrifugation and were washed twice at 12,000 × g for 5 min in PBS or EGTA (500 μl) before being subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. CCS (1.2 μg) from nonhemolytic *M. bovis* strain Gordon 26L3 was used as a control.

**Conical epithelial cell cytotoxicity assay.** Primary cultures of bovine corneal epithelial cells were derived from trephined explants of bovine corneas and were rinsed for 20 min in sterile PBS (CSL Ltd., Melbourne, Australia) containing 1% penicillin (5,000 U)-streptomycin (5,000 μg/ml) before washing in dispase II (Boehringer) overnight at 4°C. Following washing and removal of corneal stroma, explants were placed into 24-well flat-bottomed tissue culture plates (Costar, Cambridge, Mass.) with 1 ml of Dulbecco modified Eagle medium–Ham’s F-12 Medium (CSL) supplemented with 20% fetal calf serum, 20 mM l-glutamine, and 1% penicillin-streptomycin. Cell cultures were passaged less than three times prior to use in assays.

Cytotoxicity assays were similar to those previously described (16). Briefly, corneal epithelial cells were transferred to 96-well tissue culture plates, and 150 μl of fresh media was added prior to use in assays. CCS (1.2 μg) from *M. bovis* strain UQV 148NF was added to each well, and plates were incubated for 3 h at 37°C. Nonhemolytic *M. bovis* strain Gordon 26L3 and Mueller-Heintzen broth preparations were included as controls. For neutralization assays, CCS was incubated with 100 μl of culture supernatant from MAB G3/D7 for 1 h at 37°C prior to addition to corneal epithelial cell cultures. Culture supernatant from MAB 45/S, recognizing the protease of Dichelobacter nodosus, was used as a control. Cytotoxicity and neutralization of cytotoxicity were evaluated by light microscopy for disappearance of confluent corneal epithelial cell cultures.

**SDS-PAGE and Western blot analysis.** SDS-PAGE and Western blot analyses were performed by using CCS (0.9 μg of protein) or sRBC membrane preparations. Samples were separated by electrophoresis in SDS–10% polyacrylamide gels and were stained with Coomassie blue-picric acid. For Western blot analysis, proteins were transferred via a wet transfer system (Bio-Rad, Richmond, Calif.) following SDS-PAGE, and nitrocellulose membranes were blocked with 5% skim milk powder in Tris-buffered saline–0.5% Tween 20. Following washing in Tris-buffered saline–0.5% Tween 20, blots were incubated with a 1:5 dilution of tissue culture supernatant of MAB G3/D7 before further washing and addition of horseradish peroxidase-conjugated rabbit anti-mouse IgG (Sigma). Bound immunoglobulin was detected by using ECL substrate (Amersham International, Little Chalfont, United Kingdom).

**RESULTS**

**Characterization of MAbs.** Sera of mice immunized three times with *M. bovis* CCS demonstrated hemolysis-neutralizing antibody titers between 1:64 and 1:1,28. Therefore, hybridomas were generated and screened by ELISA against CCS from hemolytic *M. bovis* strain UQV 148NF. Hybridoma lines with ELISA absorbances greater than 0.8 were expanded, resulting in six different clones. All hybridoma cell lines produced antibodies belonging to the IgG₂ subclass, except for one, MAB 1/H₈, which produced antibodies of the IgG₃ subclass (Table 1).

Hybridoma culture supernatants positive by ELISA were also screened by hemolysis inhibition assay, and single cell clones obtained by limiting dilution were tested for antigen specificity and hemolysis neutralization. This resulted in the isolation of one clone, MAB G3/D7, which produced antibodies with hemolysis-neutralizing titers of 1:16 (Fig. 1). In addition, weak neutralization of hemolytic activity was observed with MAB 1/H₈. Culture supernatants from myeloma cell line X653 and other generated clones did not demonstrate hemolysis-neutralizing activity (Fig. 1).

**Detection of hemolysin by SDS-PAGE and Western blot analysis.** CCS from hemolytic and nonhemolytic *M. bovis* strains was subjected to SDS-PAGE and Western blot analysis. Two predominant protein bands with apparent molecular masses of 94 and 97 kDa, respectively, were observed in CCS from hemolytic *M. bovis* strain UQV 148NF following staining.

---

**TABLE 1. Summary of MAb clones generated against CCS from hemolytic *M. bovis* UQV 148NF**

<table>
<thead>
<tr>
<th>MAb</th>
<th>ELISA Hemolysis neutralization</th>
<th>Isotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/H₅</td>
<td>+</td>
<td>IgG₂</td>
</tr>
<tr>
<td>1/G₄</td>
<td>-</td>
<td>IgG₃</td>
</tr>
<tr>
<td>E6/E₈</td>
<td>+</td>
<td>IgG₂a</td>
</tr>
<tr>
<td>G3/D₇</td>
<td>+</td>
<td>IgG₂a</td>
</tr>
<tr>
<td>G3/C₅</td>
<td>+</td>
<td>IgG₂a</td>
</tr>
<tr>
<td>1/H₈</td>
<td>+</td>
<td>IgG₃</td>
</tr>
</tbody>
</table>

---

**FIG. 1. Screening for hemolysis neutralization of CCS incubated with sRBC.** Lanes 1 to 7, twofold serial dilutions of supernatant from MAB clones; Row A, 1/E₆; B, 1/H₈; C, 3/F₂; D, 4/G₁₁; E, G3/D₇; F, 2/H₅; G, X653. Lane 6, no added MAB; lane 7, sRBC only.
molecular mass markers are indicated to the left of the figure.

26L3 following ultracentrifugation; lane 5, CCS from UQV 148NF. Protein ultracentrifugation; lane 3, CCS from Gordon 26L3; lane 4, CCS from Gordon weight filtrate from UQV 148NF; lane 2, CCS from UQV 148NF following MAb G3/D7 tissue culture supernatant diluted 1:5. Lane 1, low-molecular-weight Coomassie blue-picric acid or (B) subjected to Western blot analysis using MAb G3/D7 prior to addition to bovine corneal epithelial cells. No hemolytic activity was observed after 0, 1, or 5 min of incubation before a gradual increase in released hemoglobin was observed with total hemolysis occurring after incubation for 60 min (Table 2). No hemoglobin liberation was observed following incubation of sRBC with CCS from nonhemolytic M. bovis strain Gordon 26L3.

Resulting sRBC membrane pellets were also collected over time and were subjected to Western blot analysis by using hemolysis-neutralizing MAb G3/D7. Two predominant proteins were detected in all samples with apparent molecular weights in SDS-PAGE of 94 and 97 kDa (Fig. 5), although bound immunoglobulin was increased in samples incubated for longer periods (Fig. 5, lanes 1 to 3). Similar-sized antigens were noted in CCS controls not exposed to sRBC (Fig. 5, lane 4). However, bound MAb was not identified in sRBC membrane preparations incubated with CCS from nonhemolytic M. bovis strain Gordon 26L3 (Fig. 5, lane 5).

Hemoglobin was not released from sRBC following exposure to CCS from hemolytic M. bovis UQV 148NF in the presence of 10 mM EGTA nor following preincubation of CCS with MAb G3/D7 (Table 2). Although hemolysis was not detected, 94- and 97-kDa antigens were identified in these sRBC preparations by Western blot analysis (Fig. 5, lane 6 and 7).

**DISCUSSION**

M. bovis hemolysin is a bacterial exotoxin implicated in the pathogenicity of M. bovis, as nonhemolytic strains do not initiate disease (3). We have generated a hemolysis-neutralizing MAb (G3/D7) that identifies an antigen in CCS of hemolytic M. bovis strain UQV 148NF by Western blot analysis, enabling characterization of the hemolysin of M. bovis without further purification. The antigen identified by MAb G3/D7 had an apparent molecular mass of 94 kDa and corresponded to a measuring released hemoglobin from lysed sRBC. No lysis was observed after 0, 1, or 5 min of incubation before a gradual increase in released hemoglobin was observed with total hemolysis occurring after incubation for 60 min (Table 2). No hemoglobin liberation was observed following incubation of sRBC with CCS from nonhemolytic M. bovis strain Gordon 26L3.

Resulting sRBC membrane pellets were also collected over time and were subjected to Western blot analysis by using hemolysis-neutralizing MAb G3/D7. Two predominant proteins were detected in all samples with apparent molecular weights in SDS-PAGE of 94 and 97 kDa (Fig. 5), although bound immunoglobulin was increased in samples incubated for longer periods (Fig. 5, lanes 1 to 3). Similar-sized antigens were noted in CCS controls not exposed to sRBC (Fig. 5, lane 4). However, bound MAb was not identified in sRBC membrane preparations incubated with CCS from nonhemolytic M. bovis strain Gordon 26L3 (Fig. 5, lane 5).

Hemoglobin was not released from sRBC following exposure to CCS from hemolytic M. bovis UQV 148NF in the presence of 10 mM EGTA nor following preincubation of CCS with MAb G3/D7 (Table 2). Although hemolysis was not detected, 94- and 97-kDa antigens were identified in these sRBC preparations by Western blot analysis (Fig. 5, lane 6 and 7).

**DISCUSSION**

M. bovis hemolysin is a bacterial exotoxin implicated in the pathogenicity of M. bovis, as nonhemolytic strains do not initiate disease (3). We have generated a hemolysis-neutralizing MAb (G3/D7) that identifies an antigen in CCS of hemolytic M. bovis strain UQV 148NF by Western blot analysis, enabling characterization of the hemolysin of M. bovis without further purification. The antigen identified by MAb G3/D7 had an apparent molecular mass of 94 kDa and corresponded to a
protein detected by Coomassie blue-picric acid after SDS-PAGE of similar preparations from hemolytic *M. bovis* strain UQV 148NF. A protein was not identified in equivalent preparations from nonhemolytic *M. bovis* strain Gordon 26L3, suggesting that nonhemolytic strains do not express this protein. Alternatively, MAb G3/D7 may recognize an activated form of the toxin not present in nonhemolytic strains. Identification of a similar size protein in *M. bovis* cultures using a MAb to the *E. coli* alpha-hemolysin provides further evidence that MAb G3/D7 specifically recognizes the hemolysin (16).

MAb G3/D7 detected more than one protein band in CCS, which has been reported in the characterization of other microbial exotoxins by using neutralizing MAbs (18). Association of the hemolysin of *E. coli* with lipopolysaccharide has been proposed to account for a size and charge heterogeneity in SDS-PAGE analysis of this toxin (9), although it is not known whether *M. bovis* hemolysin associates with lipopolysaccharide. Proteins of different size may also result from posttranslational modification, as demonstrated for *M. bovis* fimbriae (25, 32), or from proteolytic cleavage. Proteolytic activity has been reported in *M. bovis* cell cultures (26) and could account for the rapid loss of activity occurring in hemolysin preparations (3). A similar phenomenon has been reported for the exotoxins of *E. coli* and *A. pleuropneumoniae* (4, 14, 31).

Previous investigations have demonstrated lysis of corneal epithelial cells by cell-free *M. bovis* extracts in vitro in addition to hemolytic activity, and it has been speculated that a separate cytotoxin exists (2, 3, 16, 17; L. W. George and G. M. Kagonyera, 15 January 1990, international patent application no. PCT/US90/00106). Therefore, MAb G3/D7 was used to investigate whether more than one exotoxin is secreted by hemolytic *M. bovis* strains. Our study demonstrated corneal epithelial cell toxicity could be neutralized following preincubation of hemolytic *M. bovis* toxin preparations with a single (epitope-specific) hemolysis-neutralizing MAb. The most plausible explanation for this observation is that hemolytic and cytotoxic activities are due to the action of a single toxin. However, the existence of a common epitope on different toxins cannot be excluded. This would require control by a common regulatory gene to enable simultaneous expression, as reported in the regulation of virulence factors of *Bordetella pertussis* (38). Alternatively, MAb G3/D7 may have recognized an accessory protein required for lysis to proceed as described for the RTX toxins (24).

**FIG. 4.** Neutralization of corneal epithelial cytotoxicity using MAb G3/D7. Incubation of bovine corneal epithelial cells with CCS from (A) hemolytic *M. bovis* UQV 148NF and (B) nonhemolytic *M. bovis* Gordon 26L3. Preincubation of CCS from *M. bovis* UQV 148NF prior to addition to corneal epithelial cells with a 1:5 dilution of MAb tissue culture supernatant from (C) MAb G3/D7 and (D) MAb against *D. nodosus*.

**FIG. 5.** Western blot detection of hemolysin bound to sRBC over time using a 1:5 dilution of MAb G3/D7 tissue culture supernatant. Lanes 1 to 3, different incubation periods of sRBC with hemolytic CCS from UQV 148NF: lane 1, 60 min; lane 2, 10 min; lane 3, 0 min; lane 4, CCS from *M. bovis* UQV 148NF without sRBC; lane 5, nonhemolytic CCS incubated with sRBC for 60 min; lane 6, hemolytic CCS incubated with MAb G3/D7 prior to addition to sRBC; lane 7, hemolytic CCS incubated with sRBC in the presence of 10 mM EGTA. Protein molecular mass markers are indicated to the left of the figure.

**TABLE 2.** Hemolytic activity of CCS from *M. bovis* over time

<table>
<thead>
<tr>
<th><em>M. bovis</em> CCS sample incubated with sRBC</th>
<th>Time (min)</th>
<th>A_{545}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemolytic CCS</td>
<td>0</td>
<td>0.004</td>
</tr>
<tr>
<td>Hemolytic CCS</td>
<td>5</td>
<td>0.006</td>
</tr>
<tr>
<td>Hemolytic CCS</td>
<td>10</td>
<td>0.159</td>
</tr>
<tr>
<td>Hemolytic CCS</td>
<td>20</td>
<td>0.160</td>
</tr>
<tr>
<td>Hemolytic CCS</td>
<td>23</td>
<td>0.162</td>
</tr>
<tr>
<td>Hemolytic CCS plus EGTA</td>
<td>60</td>
<td>0.180</td>
</tr>
<tr>
<td>Hemolytic CCS plus MAb G3/D7</td>
<td>60</td>
<td>0.004</td>
</tr>
<tr>
<td>Nonhemolytic CCS</td>
<td>60</td>
<td>0.001</td>
</tr>
<tr>
<td>Distilled water</td>
<td>60</td>
<td>0.178</td>
</tr>
</tbody>
</table>
The unique neutralization properties of MAb G3/D7 presented the opportunity to investigate binding of the hemolysin to cell membranes. Previously, investigations using pore-forming bacterial exotoxin preparations, including an M. bovis hemolysin preparation, have suggested that osmotic lysis occurs following a rapid influx of Ca\(^{2+}\) (7, 8, 11, 12, 36). This effect was concentration dependent, suggesting time of exposure and toxin load were influencing factors (36). In agreement with previous reports, our investigations also demonstrated increased lysis of sRBC over time after exposure to M. bovis hemolysin. In addition, Western blot analysis using MAb G3/D7 detected a rapid initial binding step of toxin to sRBC, and bound protein identified before hemoglobin release was detected spectrophotometrically. A role for extracellular Ca\(^{2+}\) in the lytic process was supported by the absence of sRBC lysis in the presence of 10 mM EGTA. However, MAb G3/D7 recognized membrane-bound protein in these sRBC preparations, indicating binding of toxin to target cells was able to proceed unhindered. This does not reject a requirement of Ca\(^{2+}\) in the binding of M. bovis hemolysin to sRBC membranes, as Ca\(^{2+}\) was not excluded from bacterial growth medium in the preparation of CCS. Toxin-incorporated Ca\(^{2+}\) may be inaccessible to EGTA and, therefore, may still be able to contribute to the binding of hemolysin to sRBC membranes.

Further evidence for a two-step mechanism for hemolysis was obtained by investigating neutralization of activity following preincubation of CCS with MAb G3/D7. Preincubation with MAb G3/D7 neutralized hemolytic activity of M. bovis CCS, although Western blot analysis detected membrane-bound protein in sRBC preparations, albeit in decreased quantities. Therefore, binding of the M. bovis hemolysin to sRBC membranes can occur without lysis, which is evidence that these two events are temporally separable. This supports similar findings for the hemolysin of E. coli and the leukotoxins of A. actinomycetemcomitans and P. hemolytica (1, 13, 15, 36). The results of the present study support previous investigations suggesting that the hemolysin of M. bovis is a member of the RTX toxin family, although cloning and sequencing of the hemolysin are still required for confirmation of a relationship.

The hemolysin of M. bovis has been proposed as a vaccine candidate (3, 6). Vaccines based on fimbrial antigens with apparent molecular masses of 70 to 110 kDa by Western blot analysis (6). Therefore, a vaccine preparation containing the antigen identified by MAB G3/D7 may protect cattle from developing IBK.

In summary, MAB G3/D7 is a hemolysis-neutralizing antibody specific for M. bovis hemolysin. This MAb is currently being used to clone the hemolysin gene of M. bovis, which will allow further characterization of this toxin as a virulence factor in IBK and contribute to an understanding of its relationship with other recognized bacterial toxins.

ACKNOWLEDGMENTS

J. Woolcock (University of Queensland, Australia) generously donated M. bovis UQV 148NF. We thank Stuart Davies for advice and assistance in corneal epithelial cell culture (CRC for Lens Research and Development, New South Wales, Australia). F.M.B. thanks Philippa O’Brien for reviewing the manuscript and offering comment. F.M.B. was the recipient of a Junior Research Fellowship from the Meat Research Corporation of Australia.

REFERENCES


---

Editor: J. T. Barbieri